Transition of average drug‐to‐antibody ratio of trastuzumab deruxtecan in systemic circulation in monkeys using a hybrid affinity capture liquid chromatography‐tandem mass spectrometry
- 3 August 2023
- journal article
- research article
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 44 (5) , 380-384
Abstract
Trastuzumab deruxtecan (T‐DXd, DS‐8201a) is an antibody–drug conjugate, comprising an anti‐HER2 antibody at a drug‐to‐antibody ratio of 7–8 with the topoisomerase I inhibitor DXd. In this study, the concentrations of antibody‐conjugated DXd and total antibody were determined and observed to decrease over time following intravenous administration of T‐DXd to monkeys. The drug‐to‐antibody ratio of T‐DXd also decreased in a time‐dependent manner, which reached approximately 2.5 in 21 days after administration. It was suggested that antibody‐conjugated DXd of T‐DXd was relatively stable in vivo compared with that of other reported antibody–drug conjugates.Keywords
This publication has 14 references indexed in Scilit:
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric CancerNew England Journal of Medicine, 2020
- Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing miceXenobiotica, 2020
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast CancerNew England Journal of Medicine, 2020
- Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeysXenobiotica, 2019
- Bystander killing effect of DS‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneityCancer Science, 2016
- Where Did the Linker-Payload Go? A Quantitative Investigation on the Destination of the Released Linker-Payload from an Antibody-Drug Conjugate with a Maleimide Linker in PlasmaAnalytical Chemistry, 2016
- Quantitative bioanalysis of antibody-conjugated payload in monkey plasma using a hybrid immuno-capture LC–MS/MS approach: Assay development, validation, and a case studyJournal of Chromatography B, 2015
- Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other CancersBioconjugate Chemistry, 2015
- Elution mechanism of polypeptides in reversed‐phase liquid chromatography based on the critical threshold of organic solvent to induce abrupt change in adsorption capacity to the column packingBiomedical Chromatography, 2007
- Highly sensitive and quantitative analysis of polyeptides using a new gradient system based on an abrupt change in adsorption of polypeptide to the reversed‐phase column packingBiomedical Chromatography, 2007